Digoxin Inhibits Blood Vessel Density and HIF-1α Expression in Castration-Resistant C4-2 Xenograft Prostate Tumors

被引:33
作者
Gayed, Bishoy A. [1 ]
O'Malley, Katherine J. [1 ]
Pilch, Jan [1 ,3 ]
Wang, Zhou [1 ,2 ,3 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA
[3] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA
来源
CTS-CLINICAL AND TRANSLATIONAL SCIENCE | 2012年 / 5卷 / 01期
基金
美国国家卫生研究院;
关键词
castration resistant prostate cancer; digoxin; angiogenesis; hypoxia-inducible factor 1 alpha (HIF-1 alpha); HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PROLIFERATION; ANGIOGENESIS; DIGITALIS;
D O I
10.1111/j.1752-8062.2011.00376.x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: Recent studies suggest a potential application for digoxin in the prevention and/or treatment of prostate cancer. However, the effect of digoxin on androgen receptor (AR)-positive prostate tumor in vivo is not clear. This study is designed to determine if digoxin can inhibit AR-positive xenograft prostate tumors. Materials and Methods: Athymic male nude mice were utilized to establish subcutaneous C4-2 castration-resistant prostate tumors. The animals were castrated and then treated with daily intraperitoneal (i.p.) injection of digoxin at 2 mg/kg along with vehicle controls for 7 consecutive days. Tumor growth was determined by measuring tumor volume changes, blood vessel density by immunostaining of CD31, and cell proliferation by BrdU labeling. The expression of HIF-1 alpha in C4-2 tumors was measured by Western blot and real-time RT-PCR. Results: Digoxin inhibited blood vessel density about fourfold and down-regulated HIF-1 alpha expression at both mRNA and protein levels. However, digoxin did not inhibit C4-2 tumor growth. Conclusions: Digoxin is a potent inhibitor of HIF-1 alpha signaling pathway and blood vessel formation in C4-2 castration-resistant prostate tumors. Clin Trans Sci 2012; Volume 5: 39-42
引用
收藏
页码:39 / 42
页数:4
相关论文
共 16 条
[1]  
[Anonymous], PROSTATE CANC DISCOV
[2]   TUMOR MEASUREMENT IN THE NUDE-MOUSE [J].
EUHUS, DM ;
HUDD, C ;
LAREGINA, M ;
JOHNSON, FE .
JOURNAL OF SURGICAL ONCOLOGY, 1986, 31 (04) :229-234
[3]   Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach [J].
Fitzpatrick, John M. ;
Anderson, John ;
Sternberg, Cora N. ;
Fleshner, Neil ;
Fizazi, Karim ;
Rebillard, Xavier ;
Dogliotti, Luigi ;
Conti, Giario ;
Turesson, Ingela ;
James, Nicholas ;
Heidenreich, Axel ;
Solsona, Eduardo ;
Guillem, Vicente ;
Herchenhorn, Daniel ;
Moul, Judd ;
van Moorselaar, Jeroen ;
Coetzee, Lance J. E. ;
Wilson, Andrew ;
Bamias, Aristotelis ;
De Wit, Ronald ;
Chrisofos, Michael .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 68 :S9-S22
[4]  
Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
[5]  
Heidenreich A, 2008, EUR UROL, V53, P68, DOI 10.1016/j.eururo.2007.09.002
[6]  
Lekas A, 2006, ANTICANCER RES, V26, P2989
[7]   TUMOR ANGIOGENESIS AND TUMOR-CELL PROLIFERATION AS PROGNOSTIC INDICATORS IN GASTRIC-CARCINOMA [J].
MAEDA, K ;
CHUNG, YS ;
TAKATSUKA, S ;
OGAWA, Y ;
ONODA, N ;
SAWADA, T ;
KATO, Y ;
NITTA, A ;
ARIMOTO, Y ;
KONDO, Y ;
SOWA, M .
BRITISH JOURNAL OF CANCER, 1995, 72 (02) :319-323
[8]  
Pipinikas C, 2008, BIOMARKERS, V13, P680, DOI [10.1080/13547500802591992, 10.1080/13547500802591992 ]
[9]  
Stenkvist B, 1999, ONCOL REP, V6, P493
[10]  
STENKVIST B, 1980, ANAL QUANT CYTOL, V2, P49